We used the PI3K/AKT inhibitor LY294002 to block the PI3K/AKT pathway and found that LY294002 significantly suppressed tumour growth and down‐regulated expression of GLUT1, HK II and LDHA in cells overexpressing SLC1A3. This evidence concerns the gene AKT1 and neoplasm.